文献速递白血病

低等位基因比值FLT3-ITD与NPM1突变急性髓系白血病的预后影响

Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2018-01-01

研究纳入147例FLT3-ITD突变阳性急性髓系白血病患者,按等位基因比值(AR)低(<0.5)或高(≥0.5)分组,分析首次完全缓解(CR1)期异基因造血干细胞移植(allo-HSCT)的预后影响。NPM1突变阳性且FLT3-ITD低AR组总生存率为41.3%,并未显示有利结局;该组中行allo-HSCT者无复发生存(P=.013)和总生存(P=.003)显著更优,多因素分析显示CR1期allo-HSCT是唯一有利预后因素(RFS P<.001;OS P<.001)。

要点

  • NPM1突变阳性且FLT3-ITD低AR的AML总生存率为41.3%,未显示有利预后。
  • 该组中CR1期行allo-HSCT者较未行者RFS P=.013、OS P=.003显著更优。
  • 多因素分析显示CR1期allo-HSCT是唯一有利预后因素(RFS P<.001;OS P<.001)。

核心结论

  • 本研究发现,NPM1突变阳性且FLT3-ITD低AR的AML若未在CR1期行allo-HSCT,预后不良。

研究设计与样本

  • 研究纳入147例FLT3-ITD基因突变阳性AML患者,按FLT3-ITD等位基因比值(AR)分为低AR组(<0.5)和高AR组(≥0.5),分析CR1期行allo-HSCT的预后影响。

主要发现

  • NPM1突变阳性且FLT3-ITD低AR的AML与有利结局无关,总生存率为41.3%。
  • 该组中CR1期行allo-HSCT者较未行者结局显著更优:无复发生存P=.013,总生存P=.003。
  • 多因素分析确定CR1期allo-HSCT是唯一有利预后因素(RFS P<.001;OS P<.001)。

关键数值与推荐

  • 欧洲白血病网(ELN)认为,NPM1突变阳性且FLT3-ITD等位基因比值<0.5(低AR)的AML预后良好,不积极推荐在首次完全缓解(CR1)期行异基因造血干细胞移植(allo-HSCT)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the opinion of the European LeukemiaNet (ELN), nucleophosmin member 1 gene mutation (NPM1 mut)-positive acute myeloid leukemia (AML) with an fms-like kinase 3-internal tandem duplication (FLT3-ITD) allele ratio (AR) <0.5 (low AR) has a favorable prognosis, and allogeneic hematopoietic stem cell transplant (allo-HSCT) in the first complete remission (CR1) period is not actively recommended. We studied 147 patients with FLT3-ITD gene mutation-positive AML, dividing them into those with low AR and those with AR of ≥0.5 (high AR), and examined the prognostic impact according to allo-HSCT in CR1. Although FLT3-ITD AR and NPM1 mut are used in the prognostic stratification, we found that NPM1 mut-positive AML with FLT3-ITD low AR was not associated with favorable outcome (overall survival [OS], 41.3%). Moreover, patients in this group who underwent allo-HSCT in CR1 had a significantly more favorable outcome than those who did not (relapse-free survival [RFS] P = .013; OS P = .003). Multivariate analysis identified allo-HSCT in CR1 as the sole favorable prognostic factor (RFS P < .001; OS P < .001). The present study found that prognosis was unfavorable in NPM1 mut-positive AML with FLT3-ITD low AR when allo-HSCT was not carried out in CR1.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018. PMID: 30341082. doi:10.1182/bloodadvances.2018020305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。